Lushang Freda Pharmaceutical Co.,Ltd. (SHA:600223)
6.55
-0.24 (-3.53%)
Apr 28, 2026, 3:00 PM CST
SHA:600223 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 2,895 | 2,948 | 1,734 | 4,318 | 5,139 |
Cash & Short-Term Investments | 2,895 | 2,948 | 1,734 | 4,318 | 5,139 |
Cash Growth | -1.79% | 70.04% | -59.85% | -15.97% | 1.27% |
Accounts Receivable | 509.05 | 511.85 | 599.06 | 428.31 | 306.23 |
Other Receivables | 47.67 | 31.67 | 3,062 | 1,307 | 1,226 |
Receivables | 556.72 | 543.52 | 3,661 | 1,740 | 1,532 |
Inventory | 437.16 | 558.71 | 525.44 | 46,047 | 48,204 |
Prepaid Expenses | 0 | 0.08 | - | 491.91 | 608.15 |
Other Current Assets | 94.07 | 93.47 | 64.02 | 3,032 | 3,187 |
Total Current Assets | 3,983 | 4,144 | 5,984 | 55,629 | 58,670 |
Property, Plant & Equipment | 1,199 | 1,192 | 1,203 | 1,382 | 1,345 |
Long-Term Investments | 187.84 | 168.53 | 191.76 | 926.97 | 874.1 |
Goodwill | 153.74 | 153.74 | 153.74 | 155.59 | 160.33 |
Other Intangible Assets | 168.02 | 163.22 | 148.7 | 196.5 | 210.1 |
Long-Term Deferred Tax Assets | 27.61 | 29.82 | 23.66 | 105.04 | 101.25 |
Long-Term Deferred Charges | 84.04 | 91.11 | 53.96 | 52.34 | 40.51 |
Other Long-Term Assets | 54.26 | 58.73 | 58.26 | 26.22 | 13.92 |
Total Assets | 5,858 | 6,000 | 7,818 | 58,474 | 61,415 |
Accounts Payable | 289.39 | 413.35 | 452.98 | 9,266 | 8,694 |
Accrued Expenses | 139.48 | 136.53 | 127.32 | 1,003 | 948.47 |
Short-Term Debt | 121.05 | 212.12 | 705.22 | 2,270 | 3,219 |
Current Portion of Long-Term Debt | 1.01 | 12.51 | 790.34 | 3,222 | 2,307 |
Current Portion of Leases | 4.59 | 9.21 | 8.16 | 5.68 | 1.99 |
Current Income Taxes Payable | 19.08 | 16.35 | 9.52 | 26.59 | 18.81 |
Current Unearned Revenue | 112.01 | 122.97 | 108.44 | 17,869 | 21,686 |
Other Current Liabilities | 159.52 | 183.3 | 199.78 | 16,944 | 14,217 |
Total Current Liabilities | 846.13 | 1,106 | 2,402 | 50,606 | 51,093 |
Long-Term Debt | 6 | 44.55 | 665.04 | 2,215 | 3,751 |
Long-Term Leases | 4.29 | 7.53 | 12.98 | 21.37 | 7.69 |
Long-Term Unearned Revenue | 51.81 | 51.23 | 55.18 | 55.63 | 59.17 |
Long-Term Deferred Tax Liabilities | 1.89 | 2.31 | 2.73 | 8.55 | 5.24 |
Total Liabilities | 910.12 | 1,212 | 3,138 | 52,907 | 54,916 |
Common Stock | 1,017 | 1,017 | 1,017 | 1,017 | 1,009 |
Additional Paid-In Capital | 614.02 | 612.86 | 612.51 | 617.8 | 616.38 |
Retained Earnings | 2,602 | 2,475 | 2,385 | 2,082 | 2,202 |
Comprehensive Income & Other | - | - | 0.29 | 0.33 | 900 |
Total Common Equity | 4,233 | 4,105 | 4,015 | 3,717 | 4,727 |
Minority Interest | 714.95 | 683.47 | 665.37 | 1,850 | 1,773 |
Shareholders' Equity | 4,948 | 4,788 | 4,680 | 5,567 | 6,500 |
Total Liabilities & Equity | 5,858 | 6,000 | 7,818 | 58,474 | 61,415 |
Total Debt | 136.94 | 285.92 | 2,182 | 7,735 | 9,287 |
Net Cash (Debt) | 2,758 | 2,662 | -448.16 | -3,417 | -4,149 |
Net Cash Growth | 3.62% | - | - | - | - |
Net Cash Per Share | 2.64 | 2.62 | -0.44 | -3.01 | -4.01 |
Filing Date Shares Outstanding | 1,017 | 1,017 | 1,017 | 1,017 | 1,009 |
Total Common Shares Outstanding | 1,017 | 1,017 | 1,017 | 1,017 | 1,009 |
Working Capital | 3,137 | 3,037 | 3,583 | 5,023 | 7,577 |
Book Value Per Share | 4.16 | 4.04 | 3.95 | 3.66 | 3.79 |
Tangible Book Value | 3,911 | 3,788 | 3,712 | 3,365 | 4,357 |
Tangible Book Value Per Share | 3.85 | 3.73 | 3.65 | 3.31 | 3.43 |
Buildings | 1,089 | 1,045 | 917 | 1,312 | 1,294 |
Machinery | 738.73 | 681.06 | 620.81 | 604.52 | 551.66 |
Construction In Progress | 13.99 | 16.12 | 131.36 | 72.95 | 40.99 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.